| Id: | acc3430 |
| Group: | 2sens |
| Protein: | PERK |
| Gene Symbol: | EIF2AK3 |
| Protein Id: | Q9NZJ5 |
| Protein Name: | E2AK3_HUMAN |
| PTM: | phosphorylation |
| Site: | Thr981 |
| Site Sequence: | LTPMPAYARHTGQVGTKLYMS |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | MCF-7 |
| Disease Info: | |
| Drug: | TRAIL |
| Drug Info: | TRAIL is a type of protein - based drug that has been studied for its potential anti - cancer properties by inducing apoptosis in tumor cells. |
| Effect: | increase |
| Effect Info: | "Treatment with BIX - 01294 upregulates PERK phosphorylation, participates in the activation of the UPR pathway, promotes CHOP expression and upregulates DR5, and renders cells sensitive to TRAIL." |
| Note: | Non-conventional drugs |
| Score: | 4.5 |
| Pubmed(PMID): | 29964331 |
| Sentence Index: | 29964331_2-3 |
| Sentence: | "However, breast cancer cells are generally resistant to TRAIL, thus limiting its therapeutic potential. In this study, we found that BIX-01294, a selective inhibitor of euchromatin histone methyltransferase 2/G9a, is a strong TRAIL sensitizer in breast cancer cells." |
Sequence & Structure:
MERAISPGLLVRALLLLLLLLGLAARTVAAGRARGLPAPTAEAAFGLGAAAAPTSATRVPAAGAVAAAEVTVEDAEALPAAAGEQEPRGPEPDDETELRPRGRSLVIISTLDGRIAALDPENHGKKQWDLDVGSGSLVSSSLSKPEVFGNKMIIPSLDGALFQWDQDRESMETVPFTVESLLESSYKFGDDVVLVGGKSLTTYGLSAYSGKVRYICSALGCRQWDSDEMEQEEDILLLQRTQKTVRAVGPRSGNEKWNFSVGHFELRYIPDMETRAGFIESTFKPNENTEESKIISDVEEQEAAIMDIVIKVSVADWKVMAFSKKGGHLEWEYQFCTPIASAWLLKDGKVIPISLFDDTSYTSNDDVLEDEEDIVEAARGATENSVYLGMYRGQLYLQSSVRISEKFPSSPKALESVTNENAIIPLPTIKWKPLIHSPSRTPVLVGSDEFDKCLSNDKFSHEEYSNGALSILQYPYDNGYYLPYYKRERNKRSTQITVRFLDNPHYNKNIRKKDPVLLLHWWKEIVATILFCIIATTFIVRRLFHPHPHRQRKESETQCQTENKYDSVSGEANDSSWNDIKNSGYISRYLTDFEPIQCLGRGGFGVVFEAKNKVDDCNYAIKRIRLPNRELAREKVMREVKALAKLEHPGIVRYFNAWLEAPPEKWQEKMDEIWLKDESTDWPLSSPSPMDAPSVKIRRMDPFATKEHIEIIAPSPQRSRSFSVGISCDQTSSSESQFSPLEFSGMDHEDISESVDAAYNLQDSCLTDCDVEDGTMDGNDEGHSFELCPSEASPYVRSRERTSSSIVFEDSGCDNASSKEEPKTNRLHIGNHCANKLTAFKPTSSKSSSEATLSISPPRPTTLSLDLTKNTTEKLQPSSPKVYLYIQMQLCRKENLKDWMNGRCTIEERERSVCLHIFLQIAEAVEFLHSKGLMHRDLKPSNIFFTMDDVVKVGDFGLVTAMDQDEEEQTVLTPMPAYARHTGQVGTKLYMSPEQIHGNSYSHKVDIFSLGLILFELLYPFSTQMERVRTLTDVRNLKFPPLFTQKYPCEYVMVQDMLSPSPMERPEAINIIENAVFEDLDFPGKTVLRQRSRSLSSSGTKHSRQSNNSHSPLPSN
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| EIF2AK3-Ser404 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.974 | ||||
| COAD | |||||
| HGSC | 1.579 | ||||
| ccRCC | 0.387 | ||||
| GBM | 0.07 | ||||
| HNSC | 0.184 | ||||
| LUAD | 0.272 | ||||
| LUSC | -0.245 | ||||
| non_ccRCC | 0.654 | ||||
| PDAC | -0.928 | ||||
| UCEC | |||||
| EIF2AK3-Ser537 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.088 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 1.35 | ||||
| LUSC | -1.063 | ||||
| non_ccRCC | |||||
| PDAC | -0.199 | ||||
| UCEC | |||||
| EIF2AK3-Ser564 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.021 | ||||
| COAD | -1.697 | ||||
| HGSC | 2.192 | ||||
| ccRCC | -0.232 | ||||
| GBM | -0.048 | ||||
| HNSC | -0.516 | ||||
| LUAD | 0.425 | ||||
| LUSC | 0.147 | ||||
| non_ccRCC | 0.49 | ||||
| PDAC | -0.74 | ||||
| UCEC | |||||
| EIF2AK3-Ser660 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.439 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.68 | ||||
| GBM | 0.12 | ||||
| HNSC | |||||
| LUAD | 1.11 | ||||
| LUSC | -0.471 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK3-Ser705 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | |||||
| HNSC | -0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK3-Ser941 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.741 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -1.96 | ||||
| GBM | 0.242 | ||||
| HNSC | 0.29 | ||||
| LUAD | |||||
| LUSC | 0.684 | ||||
| non_ccRCC | |||||
| PDAC | 0.004 | ||||
| UCEC | |||||
| EIF2AK3-Ser943 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.617 | ||||
| COAD | |||||
| HGSC | 2.07 | ||||
| ccRCC | 0.226 | ||||
| GBM | -0.082 | ||||
| HNSC | -0.331 | ||||
| LUAD | -0.373 | ||||
| LUSC | -0.018 | ||||
| non_ccRCC | 0.69 | ||||
| PDAC | -0.564 | ||||
| UCEC | |||||
| EIF2AK3-Ser945 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.953 | ||||
| HNSC | |||||
| LUAD | -1.041 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | 0.089 | ||||
| UCEC | |||||
| EIF2AK3-Ser964 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| EIF2AK3-Thr406 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | 0.694 |
| HGSC | |
| ccRCC | |
| GBM | |
| HNSC | -1.146 |
| LUAD | |
| LUSC | 0.452 |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | P | Alzheimer's disease | Phosphorylation | 24319643 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
